Development and testing of autologous in vitro models for their ability to mimic the immune system’s response toward immunotherapies
Immunotherapy aims to enhance the immune system’s response to cancer. Different immunotherapies exist, such as cytokine therapies and immune checkpoint inhibitors. The FDA has approved immunomodulatory drugs, such as Proleukin, a recombinant IL-2 cytokine, Nivolumab, and Avelumab, which are immune checkpoint inhibitors. However, these drugs lead to side effects in patients known as immune-related